Scottish Equity Partners (SEP) has been appointed by LDC to manage its healthcare and biotechnology portfolio. SEP will provide investment advice on LDC’s portfolio of life science and healthcare companies, which includes Dundee-based cancer therapeutics specialist Cyclacel.
The firm has also appointed Jan Rutherford, who has over ten years’ experience in the sector, to join SEP’s expanding healthcare and life sciences group from her previous role as vice president, life sciences at Dresdner Kleinwort Capital in London.
Rutherford moved into the venture capital industry in 2000 having established a successful track record in the European business development team of Quintiles Transnational product development division. Prior to joining Quintiles she spent five years working in international clinical research across a range of therapeutic indications for Merck Sharp & Dohme and Sandoz/Novartis.
SEP managing director Calum Paterson said: “Jan? brings valuable research and development experience from the pharmaceutical industry.”